[go: up one dir, main page]

ZA200301634B - Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin. - Google Patents

Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin. Download PDF

Info

Publication number
ZA200301634B
ZA200301634B ZA200301634A ZA200301634A ZA200301634B ZA 200301634 B ZA200301634 B ZA 200301634B ZA 200301634 A ZA200301634 A ZA 200301634A ZA 200301634 A ZA200301634 A ZA 200301634A ZA 200301634 B ZA200301634 B ZA 200301634B
Authority
ZA
South Africa
Prior art keywords
dosing regimen
subject
interferon
interferon dosing
ability
Prior art date
Application number
ZA200301634A
Other languages
English (en)
Inventor
Loretta Itri
Peter Bowers
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of ZA200301634B publication Critical patent/ZA200301634B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200301634A 2000-08-02 2003-02-27 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin. ZA200301634B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22253800P 2000-08-02 2000-08-02

Publications (1)

Publication Number Publication Date
ZA200301634B true ZA200301634B (en) 2004-06-22

Family

ID=22832621

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301634A ZA200301634B (en) 2000-08-02 2003-02-27 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin.

Country Status (17)

Country Link
US (1) US20020052317A1 (pt)
EP (1) EP1325324A4 (pt)
JP (1) JP2004505114A (pt)
KR (1) KR20030043924A (pt)
CN (1) CN1466680A (pt)
AU (1) AU2001281047A1 (pt)
BR (1) BR0113179A (pt)
CA (1) CA2417550A1 (pt)
CZ (1) CZ2003311A3 (pt)
HK (1) HK1054432A1 (pt)
HU (1) HUP0303056A2 (pt)
MX (1) MXPA03001039A (pt)
PL (1) PL365664A1 (pt)
RU (1) RU2003102887A (pt)
WO (1) WO2002010743A1 (pt)
YU (1) YU7503A (pt)
ZA (1) ZA200301634B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6833351B2 (en) * 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
WO2003012432A1 (en) * 2001-08-02 2003-02-13 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin and anti-tumor necrosis factor alpha combination therapy
US20040002476A1 (en) * 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
BRPI0411155A (pt) * 2003-05-12 2006-07-11 Affymax Inc composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
SI1625156T1 (sl) * 2003-05-12 2013-02-28 Affymax, Inc. Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
CA2548454C (en) * 2003-12-04 2013-12-31 Kyowa Hakko Kogyo Co., Ltd. Medicament comprising recombinant antibody against chemokine receptor ccr4
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8563253B2 (en) * 2006-08-30 2013-10-22 Metanomics Gmbh Means and method for diagnosing hemolytic anemia
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2773778B1 (en) * 2011-10-31 2020-11-18 Merck Sharp & Dohme Corp. Methods of preparing lyophilized spherical-shaped pellets of biological materials
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
DE69632062T2 (de) * 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
YU7503A (sh) 2006-03-03
KR20030043924A (ko) 2003-06-02
AU2001281047A1 (en) 2002-02-13
HUP0303056A2 (hu) 2003-12-29
CA2417550A1 (en) 2002-02-07
MXPA03001039A (es) 2004-09-10
EP1325324A1 (en) 2003-07-09
CN1466680A (zh) 2004-01-07
US20020052317A1 (en) 2002-05-02
EP1325324A4 (en) 2004-11-10
RU2003102887A (ru) 2004-07-27
WO2002010743A1 (en) 2002-02-07
JP2004505114A (ja) 2004-02-19
HK1054432A1 (zh) 2003-11-28
BR0113179A (pt) 2004-06-22
CZ2003311A3 (cs) 2004-04-14
PL365664A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
US20020052317A1 (en) Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
DE60018273T2 (de) Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie
Tepler et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy
JP4220235B2 (ja) 短期及び長期の薬剤薬量決定のための方法
Stead et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers
WO2000067769A1 (en) Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
US20070248572A1 (en) Method for treating diseases with omega interferon
Morreale et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa
US20130344032A1 (en) Method of Treating Anemia Caused By Ribavirin Treatment of Hepatitis C Using Erythropoietin Alpha
Grasso et al. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage
JP2784401B2 (ja) 慢性骨髄性白血病の治療方法
Rodríguez et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers
JP2000256211A (ja) Ｈｉｖ治療薬
WO2025002410A1 (en) G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
TWI271196B (en) CML therapy
US20020182179A1 (en) HIV Therapy
Naoum et al. Treatment of herpes zoster with interferon alpha-2A.
Loewy et al. A Randomized Placebo-Controlled Trial of Recombinant Human Interleukin-11 in Cancer Patients With Severe Thrombocytopenia Due To Chemotherapy
JP2004143113A (ja) インターフェロン製剤及びその投与システム
MXPA00003346A (en) Chronic myeloid leukemia (cml) therapy